The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys.

Simone M NicholsonKerry A CaseyMichele GunsiorStacey DrabicWilliam IversonHalie CookStephen ScottTerry O'DaySubramanya KaranthRakesh DixitPatricia C Ryan

Published in: British journal of pharmacology (2020)

VIB4920 demonstrated an acceptable safety profile in monkeys. VIB4920 showed favourable pharmacokinetics, dose-dependent inhibition of a neoantigen-specific immune response and no adverse effects on immune function following long-term use. Our data support the use of VIB4920 in clinical trials.

Keyphrases

immune response
clinical trial
electronic health record
randomized controlled trial
dendritic cells
emergency department
deep learning
data analysis
adverse drug
artificial intelligence